Epredia expands its Anatomical Pathology division in Europe through the acquisition of Microm Microtech France and Laurypath


Epredia, a leader in the field of precision cancer diagnostics, announced today that Microm Microtech France (MMFrance) and Laurypath, two anatomical pathology segment supplier companies, have been acquired by Epredia’s parent company, PHC Holdings Corporation [TSE 6523], as part of a strategic expansion of Epredia’s European presence.

Founded in 1987 in Lyon, France, MMFrance and Laurypath manufacture and provide anatomical pathology products and services to laboratories across France. Comprehensive technical support and regional supply of reagents and other consumables for cancer diagnostics are the companies’ main priorities. Both businesses will function as fully-owned divisions of PHC Holdings Corporation as of right now.

Through this deal, Laurypath’s production facility for reagents and fixatives for tissue processing will be acquired by Epredia. These items, which are employed in all anatomical pathology laboratories, are in great demand due to the expanding demand for complicated oncology testing. They meet the demands of both research and clinical application. Epredia anticipates that producing and distributing products from regional suppliers will lessen the environmental impact of catering to European customers. Additionally, PHC Group plans to use this acquisition to fund partnerships with European university hospitals engaged in rare illness and cancer research that depend on lab supplies.

“ We are delighted to add MMFrance and Laurypath to the PHC group to support the growth of Epredia’s global business. Our customers in anatomical pathology laboratories require a consistent supply of quality diagnostic products and we are pleased to be able to offer a locally produced offering that overcomes some of the global logistical challenges in our industry.”

Steven Lynum, President at Epredia


“ Given Epredia’s global market coverage for cancer diagnostics, it was a natural step for our company to become part of the PHC Group. Epredia products are used an average of 44 times per second in cancer diagnostics and we are proud to now be part of one of the world leaders in anatomical pathology.”

Daniel Pierron, Founder of MMFrance

Next Post

CVS Health to Acquire Signify Health

A definitive agreement between CVS Health and Signify Health states that CVS Health will buy Signify Health for $30.50 per share in cash, for a total transaction value of almost $8 billion. In terms of value-based care, provider enablement, and health risk assessments, Signify Health is a pioneer. Signify Health […]